Ultrasonic blood flow parameters combined with amino-transferase to platelet ratio index to evaluate the value of portal vein thrombosis in cirrhosis

Abstract

Abstract: Objective To evaluate the value of ultrasound blood flow parameters combined with aminotransferase to platelet ratio index (APRI) in the assessment of portal vein thrombosis (PVT) in liver cirrhosis. Methods Ninety-five patients with cirrhosis who underwent splenectomy from May 2021 to December 2023 were selected and divided into non-developing group and developing group according to whether PVT occurred one week after surgery. The ultrasound blood flow parameters [portal vein diameter (PVD), portal vein velocity (PVV), splenic vein diameter], APRI and clinical data of the two groups were compared to analyze the influencing factors of postoperative PVT in patients with cirrhosis, and analyze the predictive value of PVD, PVV, APRI and their combination on postoperative PVT in patients with cirrhosis. Results One week after operation, 31 cases had PVT, the incidence was 32.63%, and the remaining 64 cases did not have PVT. The PVV in the developing group was lower than non-developing group (P<0.05), and the PVD, splenic vein diameter and APRI in the developing group were higher than non-developing group (P<0.05). The levels of fibrinogen (Fib) and D-dimer (D-D) in the developing group were higher than non-developing group (P<0.05).Binary Logistic regression analysis showed that PVD (OR=3.445, 95%CI: 1.515~7.837), APRI (OR=2.835, 95%CI: 1.246~6.449), PVV (OR=0.697, 95%CI: 0.306-1.585) and D-D (OR=3.850, 95%CI: 1.692-8.757) were the influencing factors of postoperative PVT in patients with cirrhosis (P<0.05). The area under the curve (AUC) values of APRI, PVV, and PVD were 0.819, 0.826, and 0.794, while the combination of APRI, PVV and PVD (AUC=0.901) showed superior predictive performance compared to individual parameters (all P<0.05). Conclusion PVD and APRI combined with PVV have higher value in predicting the risk of postoperative PVT.

Key words: Ultrasonic blood flow parameters, Amino-transferase to platelet ratio index, Liver cirrhosis, Portal vein thrombosis, Predictive value

WANG Qian, LING Shuang, LI Jing, XU Jia-qi, WANG Fang-xu. Ultrasonic blood flow parameters combined with amino-transferase to platelet ratio index to evaluate the value of portal vein thrombosis in cirrhosis[J]. Chinese Hepatolgy, 2025, 30(4): 514-518.

References

[1] Senzolo M, Garcia-Tsao G, Garcia-Pagan J C. Current knowledge and management of portal vein thrombosis in cirrhosis[J]. J Hepatol, 2021,75(2):442-453.
[2] Ju C, Li X, Gadani S, et al. Portal vein thrombosis: diagnosis and endovascular management[J]. Rofo, 2022,194(2):169-180.
[3] Molvar C, Amin P. Portal vein thrombosis in cirrhosis: interventional treatment options[J]. Curr Gastroenterol Rep, 2021,23(12):24.
[4] 赵小利,秦博,李东风,等. 乙型肝炎肝硬化并发食管静脉曲张患者超声检测肝脏血流参数和红细胞分布宽度与淋巴细胞比值变化[J]. 实用肝脏病杂志,2023,26(4):528-531.
[5] 张文军,李雪琳. 肝硬化门静脉高压术后血栓风险与术前超声血流参数及凝血功能指标的关系[J]. 血栓与止血学,2021,27(5):725-727,731.
[6] Xing Y, Tian Z, Jiang Y, et al. A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis[J]. Ann Med, 2022,54(1):302-309.
[7] 崔燕,王婷,杨亚俊,等. 天冬氨酸氨基转移酶-血小板计数指数联合血氨对肝硬化并发肝性脑病的诊断价值[J]. 中西医结合肝病杂志,2022,32(4):331-334.
[8] 中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志,2019,27(11):846-865.
[9] 中华医学会消化病学分会肝胆疾病学组. 肝硬化门静脉血栓管理专家共识(2020年,上海)[J]. 临床肝胆病杂志,2020,36(12):2667-2674.
[10] Li J, Wu Q Q, Zhu R H, et al. Machine learning predicts portal vein thrombosis after splenectomy in patients with portal hypertension: comparative analysis of three practical models[J]. World J Gastroenterol, 2022,28(32):4681-4697.
[11] Martens K, McMurry H S, Koprowski S, et al. Anticoagulation in cirrhosis: evidence for the treatment of portal vein thrombosis and applications for prophylactic therapy[J]. J Clin Gastroenterol, 2022,56(6):536-545.
[12] Bohula E A, Berg D D, Lopes M S, et al. Anticoagulation and antiplatelet therapy for prevention of venous and arterial thrombotic events in critically Ill patients with COVID-19: COVID-PACT[J]. Circulation, 2022,146(18):1344-1356.
[13] Ruberto M F, Piras M S, Sorbello O, et al. Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk[J]. Eur Rev Med Pharmacol Sci, 2021,25(17):5518-5524.
[14] Premkumar M, Kulkarni A V, Kajal K, et al. Principles, interpretation, and evidence-based role of viscoelastic point-of-care coagulation assays in cirrhosis and liver failure[J]. J Clin Exp Hepatol, 2022,12(2):533-543.
[15] 朱海艳,范晓棠. 肝硬化并发门静脉血栓形成患者列线图预测模型分析及外部验证[J]. 实用肝脏病杂志,2022,25(6):848-852.
[16] 刘小娇,王政强,马超,等. 肝硬化门静脉血栓形成风险预测列线图模型的建立与验证[J]. 中华消化内镜杂志,2023,40(1):47-52.
[17] Dong Y, Li L. Influences of jieyu ruanjian huoxue prescription on hepatic fibrosis indices and APRI in patients with hepatitis B cirrhosis[J]. Am J Transl Res, 2021,13(7):8514-8521.
[18] Zhao L Y, Yang D D, Ma X K, et al. The prognostic value of aspartate aminotransferase to lymphocyte ratio and systemic immune-inflammation index for overall survival of hepatocellular carcinoma patients treated with palliative treatments[J]. J Cancer, 2019,10(10):2299-2311.
[19] Zanetto A, Campello E, Burra P, et al. Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis[J]. Liver Int, 2023,43(1):155-159.
[20] Wang T, Tan W, Wang X, et al. Role of precipitants in transition of acute decompensation to acute-on-chronic liver failure in patients with HBV-related cirrhosis[J]. JHEP Rep, 2022,4(10):100529.
[21] Itakura J, Kurosaki M, Setoyama H, et al. Applicability of APRI and FIB-4 as a transition indicator of liver fibrosis in patients with chronic viral hepatitis[J]. J Gastroenterol, 2021,56(5):470-478.